A2M's success means higher competition for BAL and therefore lower market share and lower likelihood of accelerated growth. Why would BAL not go down on a competitors bumper result?
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025